Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

Abstract Background Randomized controlled trials showed that sodium/glucose cotransporter-2 inhibitors (SGLT2i) protect the heart and kidney in an array of populations with type 2 diabetes (T2D) and increased cardiorenal risk. However, the extent of these benefits also in lower kidney-risk T2D popul...

Full description

Bibliographic Details
Main Authors: Meir Schechter, Cheli Melzer-Cohen, Aliza Rozenberg, Ilan Yanuv, Gabriel Chodick, Avraham Karasik, Mikhail Kosiborod, Ofri Mosenzon
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Cardiovascular Diabetology
Subjects:
SGLT2i
Cardiorenal outcomes
Real world evidence
Type 2 diabetes
Online Access:https://doi.org/10.1186/s12933-021-01362-y

Internet

https://doi.org/10.1186/s12933-021-01362-y

Similar Items